Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00

Protagonist Therapeutics (NASDAQ:PTGX) had its price objective hoisted by The Goldman Sachs Group from $65.00 to $95.00 in a report issued on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Other equities analysts have also recently issued reports about the stock. Citizens Jmp raised their price objective on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group increased their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Barclays lifted their price objective on Protagonist Therapeutics from $108.00 to $113.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings lowered Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Finally, Citigroup raised their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.00.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $91.41 on Tuesday. The business’s fifty day moving average price is $84.64 and its two-hundred day moving average price is $77.90. The firm has a market capitalization of $5.83 billion, a price-to-earnings ratio of -44.59 and a beta of 2.23. Protagonist Therapeutics has a 52 week low of $37.92 and a 52 week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. As a group, research analysts forecast that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Dinesh V. Ph D. Patel sold 4,068 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total value of $338,416.92. Following the completion of the transaction, the chief executive officer directly owned 574,505 shares of the company’s stock, valued at approximately $47,793,070.95. This represents a 0.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lewis T. Williams sold 18,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total value of $1,483,560.00. Following the completion of the sale, the director directly owned 7,825 shares in the company, valued at $644,936.50. This represents a 69.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 203,167 shares of company stock worth $16,889,199 in the last ninety days. 4.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors have recently bought and sold shares of the company. American Century Companies Inc. lifted its stake in shares of Protagonist Therapeutics by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock worth $44,990,000 after buying an additional 128,171 shares during the last quarter. Voya Investment Management LLC raised its holdings in Protagonist Therapeutics by 8.9% in the 3rd quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock valued at $20,289,000 after acquiring an additional 25,065 shares during the period. Segall Bryant & Hamill LLC bought a new position in Protagonist Therapeutics in the 2nd quarter valued at about $6,641,000. Nan Fung Trinity HK Ltd. acquired a new stake in Protagonist Therapeutics during the second quarter worth approximately $7,464,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Protagonist Therapeutics by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 388,082 shares of the company’s stock worth $21,449,000 after acquiring an additional 11,219 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.